Phenomix Sciences Revenue and Competitors

Phenomix Sciences is an early stage startup providing healthcare solutions that will enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. Our approach is based on a phenotype-driven multi-level “omics” platform supported with deep learning technology to identify chronic disease sub-types in order to individualize therapy selection and enhance treatment outcomes. Our first product is a novel blood-based test expected to launch in 2021 and will accurately predict the sub-type of obesity which can be used to guide the selection of an appropriate therapy or medical intervention. Initial data from two randomized trials demonstrates that phenotype-guided treatment selection more than doubles weight loss as compared to non-phenotype guided therapy, with an overall lower incidence of side effects and adverse events. Phenomix Sciences was founded in 2017 by two leading, NIH-funded Mayo Clinic gastroenterologists, Dr. Andres Acosta and Dr. Michael Camilleri. The company is privately held with offices in Rochester, MN and St. Paul, MN. For more information, visit us at www.phenomixsciences.com.